Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: majormember who wrote (1135)	6/22/1998 1:41:00 PM
From: majormember	Respond to of 4140

All: Below another positive post from Yahoo. All we need is NASDAQ listing. Does anyone know the nature of the delay? Regards, Skane ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Clinical tests trials are completed, with the exception of second eye treatment for a few. According to my source the treatments were 100% effective. All (repeat) All had their vision corrected to 20/20 or 20/16. Three significant impending events could have an affect on the share price. (1) NASDAQ listing (2) The soon to be released news of the successful clinical trials. (3) Templeton Group and DeMoss Foundation waiting to buy shares when relisted on the NASDAQ. These three factors may cause a spike up of the share price to the middle or upper teens. Backorders from Drs. to buy the equipment is already running in the thousands. A certain Opthamologist in Boca Raton believes that FDA approval is a "slam dunk" because of the phenominal success of the clinical trials and final FDA approval may be greately accelerated. He is so optimistic that he believes SNRS may be up an running this time next year. This could mean and eventual share price of $125. Lets hope all this turns our to be true.